SCYNEXIS Inc — Cash Flow (NASDAQ:SCYX)

Financials

Cash from operating activities 49.35 M54.56 M79.88 M60.16 M24.01 M 33.59 M Cash from investing activities 6.47 M1.17 M27.39 M34.88 M6.15 M 33.51 M Cash from financing activities 94 M67.12 M48.6 M36.72 M139 K 14.18 M Free cash flow 49.35 M53.39 M79.87 M60.16 M24.01 M 33.59 M

News

SCYNEXIS doses first patients in SCY-247 IV formulation trial

JERSEY CITY - FDA grants fast track and QIDP designations to SCYNEXIS drug

Scynexis receives 180-day extension from Nasdaq to meet listing requirements

SCYNEXIS receives $7 million annual grant for antifungal research

Guggenheim lowers SCYNEXIS stock price target to $3 after GSK trial resolution

SCYNEXIS receives $22 million from GSK as MARIO study ends

Scynexis to receive $24.3 million from GSK as MARIO study ends per new agreement

SCYNEXIS reports positive Phase 1 results for antifungal drug SCY-247

Scynexis Inc earnings beat by $0.06, revenue topped estimates

SCYNEXIS resumes Phase 3 antifungal study after FDA lift

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update